Two Oncologics Face Tough ODAC Review: Problems Of Efficacy For Schering's PegIntron And Safety For GSK's Votrient
This article was originally published in The Pink Sheet Daily
Executive Summary
The Oncologic Drugs Advisory Committee will meet Oct. 5 to evaluate the sNDA for PegIntron to treat melanoma and the NDA for Votrient to treat renal cell carcinoma.